BRIDGEWATER, N.J., Feb. 10,
2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq:
INSM), a people-first global biopharmaceutical company striving to
deliver first- and best-in-class therapies to transform the lives
of patients facing serious diseases, today announced that it will
release its fourth-quarter and full-year 2024 financial results
on Thursday, February 20, 2025.
Insmed management will host a conference call for investors
beginning at 8:00 a.m. ET on Thursday,
February 20, 2025, to discuss financial results and provide
a business update.
Shareholders and other interested parties may participate in the
conference call by dialing (888) 210-2654 (U.S.) and (646) 960-0278
(international) and referencing access code 7862189. The call will
also be webcast live on the Company's website at
www.insmed.com.
A replay of the conference call will be accessible approximately
1 hour after its completion through February
27, 2025, by dialing (800) 770-2030 (U.S.) and (609)
800-9909 (international) and referencing access code 7862189. A
webcast of the call will also be archived for 90 days under the
Investor Relations section of the Company's website at
www.insmed.com.
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical
company striving to deliver first- and best-in-class therapies to
transform the lives of patients facing serious diseases. The
Company is advancing a diverse portfolio of approved and mid- to
late-stage investigational medicines as well as cutting-edge drug
discovery focused on serving patient communities where the need is
greatest. Insmed's most advanced programs are in pulmonary and
inflammatory conditions, including a therapy approved in
the United States, Europe, and Japan to treat a chronic, debilitating lung
disease. The Company's early-stage research programs encompass a
wide range of technologies and modalities, including gene therapy,
AI-driven protein engineering, protein manufacturing, RNA
end-joining, and synthetic rescue.
Headquartered in Bridgewater, New
Jersey, Insmed has offices and research locations throughout
the United States, Europe, and Japan. Insmed is proud to be recognized as one
of the best employers in the biopharmaceutical industry, including
spending four consecutive years as the No. 1 Science Top
Employer. Visit www.insmed.com to learn more.
Contact:
Investors:
Bryan Dunn
Vice President, Investor Relations
(646) 812-4030
bryan.dunn@insmed.com
Michael V. Morabito, Ph.D.
Director, Investor Relations
(917) 936-8430
michael.morabito@insmed.com
Gianna De Palma
Manager, Investor Relations
(973) 886-2236
gianna.depalma@insmed.com
Media:
Mandy Fahey
Vice President, Corporate Communications
(732) 718-3621
amanda.fahey@insmed.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/insmed-to-host-fourth-quarter-and-full-year-2024-financial-results-conference-call-on-thursday-february-20-2025-302371620.html
SOURCE Insmed Incorporated
